Compare Johnson & Johnson (JNJ) vs Western Alliance Bancorporation (WAL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Johnson & Johnson vs Western Alliance Bancorporation — how do they compare? Johnson & Johnson trades at $259.5 (market cap $618.09B), while Western Alliance Bancorporation trades at $74.22 (market cap $8.24B). The key difference: Johnson & Johnson is far larger — about 75× Western Alliance Bancorporation's market cap, and Western Alliance Bancorporation pays the higher dividend (2.23%). Which is the better fit depends on your goals — on Pluang, investors hold Johnson & Johnson for 129 Days and Western Alliance Bancorporation for 3 Days on average.
| JNJ | WAL | |
|---|---|---|
Market Cap | $618.09B | $8.24B |
Volume | 6,050,983 | 1,387,161 |
Sector | Health | Financials |
52-Week High | $278.43 | $96.08 |
52-Week Low | $186.00 | $66.70 |
Typical Hold Time | 129 Days | 3 Days |
Enterprise Value | $646.37B | $9.76B |
Dividend Yield | 2.09% | 2.23% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Johnson & Johnson (JNJ) trades at $258.45, up 1.44% with a bearish technical signal despite recent earnings beats. The company maintains strong fundamentals with $94.19B revenue, 21.48% net margin, and robust cash flow. Analyst consensus is bullish with a $286.53 price target, though technical indicators show resistance near $260. Recent news highlights pipeline strength including Icotyde's potential $4.5B peak sales.
JNJ offers stable dividend income and pharmaceutical innovation upside, but faces patent cliff risks and competitive pressures. The stock presents value near current levels with 10.7% upside to consensus target, though technical weakness suggests potential near-term consolidation. Long-term growth drivers include oncology portfolio and Ottava surgical system development.
Western Alliance Bancorporation (WAL) trades at $74.35, down 2.29% today, with a bearish technical signal but strong fundamentals including a P/E of 8.52 and net income margin of 25.43%. Recent Q2 2026 earnings missed EPS estimates at $2.36, though revenue and profitability trends remain positive. The company launched WA VenueX, an institutional financial platform, and announced a $0.42 dividend for H2-2026.
Outlook is mixed: analyst consensus is strongly bullish with a $84.33 price target, but technical indicators signal near-term pressure. Key risks include interest rate sensitivity and regulatory changes, while institutional buying and solid valuation metrics support long-term upside potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →About Western Alliance Bancorporation
Western Alliance Bancorporation is a top-performing bank holding company that operates a dual business model: high-touch regional banking and specialized national business lines. It serves niche industries—including technology, life sciences, and homeowners associations—providing sophisticated commercial lending and treasury solutions that bridge the gap between regional service and national scale.
Read more on WAL →
